Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

NCORPORATED

Consolidated Balance Sheets

(in thousands, except share and per share data)

December 31, December 31,

2007 2006

Assets

Current assets:

Cash, cash equivalents and short-term

investments $ 16,479 $ 24,112

Short-term investments - -

Restricted cash - 407

Accounts receivable, net 250 241

Inventories - 576

Prepaid expenses 244 87

Total current assets 16,973 25,423

Long-term assets:

Restricted cash - long term 2,095 2,708

Investments 258 -

Deferred financing costs, net 170 209

Property and equipment, net 4 8

Total long-term assets 2,527 2,925

Total assets $ 19,500 $ 28,348

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $ 904 $ 7,187

Accrued project costs & other 503 1,115

Payroll liabilities 631 1,302

Interest payable 23 23

Deferred rent 115 54

Deferred income 245 -

Convertible debt 2,211 -

Debt discount
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
(Date:6/1/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/57b5qj/global_pdt ... "Global PDT Machine Industry Report 2014" report ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global PDT ... in-depth study on the current state of the ... overview of the industry including definitions, classifications, applications ...
(Date:6/1/2015)...  Boston-based Veritas Genetics is launching its mission ... personalized medicine and prevention to the forefront, allowing ... Beginning with its first product, a genetic screen ... Genetics is making its products affordable and accessible, ... genetic data which will be shared with the ...
(Date:6/1/2015)... , June 1, 2015 Esperance Pharmaceuticals ... trial of lead candidate EP-100 in ovarian cancer patients ... designed to seek and destroy cancer cells that overexpress ... receptors are over-expressed in a wide range of cancers. ... Phase II trial of EP-100 were presented at ...
Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global PDT Machine Industry Report 2014 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 2Veritas Genetics To Advance Precision Medicine And Disease Prevention 3Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... July 7 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the "Company") (Nasdaq: CHBT ... , today provides,further updates on the Company,s bulk additive operation. , ... China-Biotics gained ... and the total number of bulk customers increased to 39 by the ...
... , ... that from a single platform, scientists can efficiently profile lead compounds in their own ... ... -- Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a flexible and complete ...
... CLEVELAND , July 7 DATATRAK International, Inc. ... eClinical solutions for the clinical trials industry, today announced that ... approximately $0.53 per share with certain members of ... sold pursuant to the private placement are restricted securities and ...
Cached Biology Technology:China-Biotics Provides Further Updates on Qingpu New Facility 2China-Biotics Provides Further Updates on Qingpu New Facility 3Promega Now Offers Complete Solution for Profiling Kinase Inhibitor Compounds Against the Human Kinome 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/25/2015)... market for wearable technologies is considered to be in ... several trials and prototypes. The release of the Apple ... interest in wearables as well as accelerate sales of ... in turn will spur greater innovation from other players ... and distributors. Photo - http://photos.prnewswire.com/prnh/20150526/218287 ...
(Date:5/22/2015)... According to a new market ... Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, ... and Home) - Global Forecast to 2020", published by ... in 2015 to $6.19 Billion by 2020, at a ... data Tables and   43 Figures spread through 140 ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3
... the word "doctor" to mean "all-knowing," unfortunately, this will ... of medical professionals sometimes leads to devastating misdiagnoses that ... their patients. , But there is hope for better, ... technologies, and one Florida State University researcher is putting ...
... data for E7389 in the treatment of advanced, refractory ... E7389 is a synthetic analog of halichondrin B ... studies to have highly potent anti-cancer activity in vitro ... a type of marine sponge. , This study was ...
... shown that the immune-stimulating hormone known as interleukin-12 ... immune-system protein, as an experimental therapy for some ... to stimulate the immune system to attack certain ... sometimes used to treat melanoma, advanced kidney cancer ...
Cached Biology News:Making medicine 'smarter' 2Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer 2Study shows combination of immune substances to be safe 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... Single Cell Whole Genome Amplification Kit ... random fragmentation of genomic DNA and ... to PCR-amplifiable library molecules flanked by ... by PCR amplification of the library ...
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Biology Products: